

CITATION REPORT

List of articles citing

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

DOI: 10.1111/apt.12963

Alimentary Pharmacology and Therapeutics, 2014, 40, 1209-2

Source: <https://exaly.com/paper-pdf/58284082/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
279	When and how to use steatosis biomarkers?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 1359-60	6.1	2
278	Nonalcoholic fatty liver disease. 2015 , 1, 15080		366
277	Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 42, 582-91	6.1	11
276	Association of the Nonalcoholic Hepatic Steatosis and Its Degrees With the Values of Liver Enzymes and Homeostasis Model Assessment-Insulin Resistance Index. 2015 , 8, 260-264		20
275	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. 2015 , 9, 603-27		79
274	Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis. 2015 , 5, 314-9		8
273	Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 65-76	6.1	140
272	Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. 2015 , 15, 607		74
271	Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. 2015 , 15, 21-5		29
270	Additive Effect of Non-Alcoholic Fatty Liver Disease on Metabolic Syndrome-Related Endothelial Dysfunction in Hypertensive Patients. 2016 , 17, 456		18
269	Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population. 2016 , 89, 82-8		14
268	How to diagnose NAFLD in 2016. <i>Journal of Hepatology</i> , 2016 , 65, 643-4	13.4	29
267	Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. 2016 , 31, 848-55		106
266	Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. 2016 , 30, 282-7		40
265	Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. 2016 , 6, 24031		10
264	Associations between sitting time and non-alcoholic fatty liver diseases in Chinese male workers: a cross-sectional study. 2016 , 6, e011939		14
263	How to best diagnose NAFLD/NASH?. 2016 , 111-123		

262	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. 2016 , 59, 1121-40		275
261	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016 , 64, 1388-402	13.4	2065
260	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. 2016 , 9, 65-90		197
259	Fatty liver is an independent predictor of early carotid atherosclerosis. <i>Journal of Hepatology</i> , 2016 , 65, 95-102	13.4	67
258	Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 1071-1079	6.1	19
257	Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 83-95	6.1	125
256	Fatty liver index is a risk determinant of incident type 2 diabetes in a metabolically healthy population with obesity. <i>Obesity</i> , 2016 , 24, 1373-9	8	26
255	Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. 2016 , 20, 277-92		24
254	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. 2017 , 49, 471-483		179
253	An extended fatty liver index to predict non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2017 , 43, 229-239	5.4	18
252	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. 2017 , 40, 419-430		172
251	Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score). 2017 , 37, 1535-1543		11
250	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. 2017 , 10, 535-547		13
249	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. 2017 , 72, 57-65		80
248	Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study. 2017 , 67, 62-71		46
247	Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. 2017 , 96, e6381		8
246	Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects. 2017 , 96, e7041		25
245	NAFLD in clinical practice: Can simple blood and anthropometric markers be used to detect change in liver fat measured by H-MRS?. 2017 , 37, 1907-1915		11

244	Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm?. 2017 , 49,		12
243	Esteatosis hepática: diagnóstico y seguimiento. 2017 , 24, 378-389		0
242	External validation of non-invasive prediction models for identifying ultrasonography-diagnosed fatty liver disease in a Chinese population. 2017 , 96, e7610		14
241	Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 209	6.1	1
240	The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. <i>Lipids in Health and Disease</i> , 2017 , 16, 15	4.4	62
239	Non-invasive diagnosis of hepatic steatosis. 2017 , 11, 70-78		64
238	Nonalcoholic fatty liver disease: Evolving paradigms. 2017 , 23, 6571-6592		92
237	Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort. 2017 , 12, e0171502		54
236	Fatty Liver Index and Lipid Accumulation Product Can Predict Metabolic Syndrome in Subjects without Fatty Liver Disease. 2017 , 2017, 9279836		9
235	Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. 2018 , 42, 1900-1911		17
234	Obesity and Nonalcoholic Fatty Liver Disease. 2018 , 89-97		1
233	Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. 2018 , 50, 370-377		29
232	Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 631-644	6.1	49
231	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. 2018 , 14, 99-114		170
230	Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study. 2018 , 53, 29-33		20
229	Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes. 2018 , 33, 270-276		50
228	The relationship between fatty liver index and bone mineral density in Koreans: KNHANES 2010-2011. 2018 , 29, 181-190		10
227	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. 2018 , 67, 2001-2012		79

226	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. 2018 , 12, 351-367		34
225	Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. 2018 , 10,		98
224	A Comparison of the Liver Fat Score and CT Liver-to-Spleen Ratio as Predictors of Fatty Liver Disease by HIV Serostatus. 2018 , 2,		
223	Male-specific association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015. 2018 , 8, 15145		19
222	Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men. 2018 , 13, e0201308		25
221	Non-alcoholic fatty liver disease: Relationship with cardiovascular risk markers and clinical endpoints. 2018 , 144, 144-152		14
220	Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features. 2018 , 28, 187-194		16
219	Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome. 2018 , 116, 1-7		20
218	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. 2018 , 24, 3361-3373		203
217	Non-alcoholic fatty liver disease. 2018 , 18, 245-250		64
216	Non-alcoholic fatty liver disease and the interface between primary and secondary care. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 509-517	18.8	64
215	Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction. 2018 , 30, 1047-1054		20
214	Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham Score. 2019 , 69, 1453-1463		19
213	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. 2019 , 13, 849-866		24
212	Clinical prediction score of nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index). 2019 , 91, 544-552		12
211	Association of fatty liver index with risk of incident type 2 diabetes by metabolic syndrome status in an Eastern Finland male cohort: a prospective study. 2019 , 9, e026949		7
210	Depression is associated with non-alcoholic fatty liver disease among adults in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 590-598	6.1	30
209	Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. 2019 , 19, 187-198		10

208	Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population. 2019 , 14, e0224626		15
207	Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	8
206	A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). 2019 , 11,		39
205	Prospective study of gestational diabetes and fatty liver scores 9 to 16 years after pregnancy. 2019 , 11, 895-905		6
204	Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. 2019 , 156, 1264-1281.e4		447
203	Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. 2019 , 25, 1307-1326	79	
202	Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. 2019 , 16, 285-291		8
201	Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort. 2019 , 6, e000219		3
200	Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio Ischaemic Heart Disease Risk Factor Study Cohort. 2019 , 9, e031420		2
199	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. 2019 , 31, 393-402		8
198	Physical Activity, Fatty Liver, and Glucose Metabolism Over the Life Course: The Lifelines Cohort. 2019 , 114, 907-915		10
197	Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study. 2019 , 36, 478-491		12
196	Prediction of Liver Steatosis Applying a New Score in Subjects from the Brazilian Longitudinal Study of Adult Health. 2020 , 54, e1-e10		2
195	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. 2020 , 41,		56
194	Influence of lifestyle factors and staple foods from the Mediterranean diet on non-alcoholic fatty liver disease among older individuals with metabolic syndrome features. 2020 , 71, 110620		15
193	Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. 2020 , 67, 569-578		3
192	Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. 2020 , 129, 59-66		7
191	Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. 2020 , 19, 674-690		24

190	The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. 2020 , 3, e00127		4
189	Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease. 2020 , 72, 1556-1568		21
188	Relationship between triglyceride glucose index and the incidence of non-alcoholic fatty liver disease in the elderly: a retrospective cohort study in China. 2020 , 10, e039804		5
187	Advances in ultrasound elastography for nonalcoholic fatty liver disease. 2020 , 47, 521-533		8
186	Clinical features of COVID-19 patients with non-alcoholic fatty liver disease. 2020 , 4, 1758		34
185	A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. 2020 , 37, 4627-4640		2
184	Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with suspected non-alcoholic fatty liver disease. 2020 ,		1
183	Comparative Assessment and External Validation of Hepatic Steatosis Formulae in a Community-Based Setting. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
182	Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. 2020 , 11, 2042018820958298		6
181	Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. <i>Cardiovascular Diabetology</i> , 2020 , 19, 51	8.7	19
180	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. 2020 , 17, e1003149		18
179	Estimated Cardiorespiratory Fitness Attenuates the Impacts of Sarcopenia and Obesity on Non-Alcoholic Fatty Liver in Korean Adults. 2020 , 17,		6
178	Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. 2020 , 21,		15
177	Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. 2020 , 5, 31		13
176	Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy. 2020 , 10,		21
175	The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection. 2020 , 9,		0
174	Noninvasive Diagnosis of NAFLD and NASH. 2020 , 9,		55
173	NAFLD or comorbidities, that is the question. <i>Journal of Hepatology</i> , 2020 , 73, 723	13.4	1

172	Detection of pediatric hepatic steatosis through ultrasound backscattering analysis. 2021 , 31, 3216-3225	2
171	A branched-chain amino acid-based metabolic score can predict liver fat in children and adolescents with severe obesity. 2021 , 16, e12739	5
170	Risk factors of liver injury in patients with coronavirus disease 2019 in Jiangsu, China: A retrospective, multi-center study. 2021 , 93, 3305-3311	8
169	NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues. <i>Journal of Hepatology</i> , 2021 , 74, 482-484	13.4 24
168	Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores. 2020 , 66, 301-306	2
167	Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. 2021 , 44, 1879-1889	5
166	Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV. 2021 , 22, 445-456	1
165	Valoraci3n bioqu3mica en la enfermedad hep3tica grasa asociada a la disfunci3n metab3lica. 2021 , 2, 209-219	
164	Impact of healthy plant-based diet on abdominal visceral and liver fat contents. 2021 , 10, 136-138	0
163	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults. 2021 , 1	2
162	Fatty liver index and left ventricular mass: prospective associations from two independent cohorts. 2021 , 39, 961-969	0
161	Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. 2021 , 43, 455-472	2
160	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. 2021 , 12, 649-666	7
159	Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. 2021 , 66, 2092-2100	1
158	Biochemical assessment of metabolic associated fatty liver disease. 2021 , 2, 199-208	1
157	Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. 2021 , 51, 554-569	7
156	Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. 2021 , 31, 869-879	9
155	SHBG as a Marker of NAFLD and Metabolic Impairments in Women Referred for Oligomenorrhea and/or Hirsutism and in Women With Sexual Dysfunction. 2021 , 12, 641-646	5

154	US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score?. 2021 , 132, 204-209		5
153	Liver fat scores do not reflect interventional changes in liver fat content induced by high-protein diets. 2021 , 11, 8843		0
152	Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
151	Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. 2021 , 11,		1
150	Serum butyrylcholinesterase/HDL-cholesterol ratio and atherogenic index of plasma in patients with fatty liver disease. 2021 , 67, e04-e08		1
149	Triglycerides to high-density lipoprotein cholesterol ratio for diagnosing nonalcoholic fatty liver disease. 2021 ,		2
148	Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
147	Psoriasis and Liver Damage in HIV-Infected Patients. 2021 , 10,		0
146	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. 2021 , 41, 235-247		1
145	Activation of heat shock response improves biomarkers of NAFLD in patients with metabolic diseases. 2021 , 10, 521-533		
144	Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD. 2021 , 11,		0
143	Nonalcoholic fatty liver disease is associated with the development of obstructive sleep apnea. 2021 , 11, 13473		1
142	Urinary Phthalate Levels Associated with the Risk of Nonalcoholic Fatty Liver Disease in Adults: The Korean National Environmental Health Survey (KoNEHS) 2012-2014. 2021 , 18,		1
141	Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. 2021 , 41, 225-234		5
140	PERFORMANCE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS. 2021 , 58, 139-144		0
139	Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. 2021 , 106, e4360-e4371		1
138	Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. 2021 , 41, 2590-2600		2
137	Association of TyG index and TG/HDL-C ratio with arterial stiffness progression in a non-normotensive population. <i>Cardiovascular Diabetology</i> , 2021 , 20, 134	8.7	10

136 Diagnosis of Nonalcoholic Steatohepatitis.

135 Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean national health and nutrition examination survey (KNHANES). **2021**, 29, 1111-1118 1

134 Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. **2021**, 21, 1065-1078 1

133 Triglyceride glucose (TyG) index and the progression of liver fibrosis: A cross-sectional study. **2021**, 44, 483-487 2

132 Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity. **2021**, 37, 1867-1873 0

131 Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease. **2021**, 0

130 Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. **2021**, 3, 100381 1

129 EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *Journal of Hepatology*, **2021**, 75, 659-689 13.4 102

128 Predictive Modeling of MAFLD Based on Hsp90 α and the Therapeutic Application of Teprenone in a Diet-Induced Mouse Model. **2021**, 12, 743202 0

127 Exogenous Drug Disposition as a Diagnostic Biomarker Strategy for Non-Alcoholic Steatohepatitis. **2021**, 1

126 Screening for nonalcoholic fatty liver disease-when, who and how?. **2021**, 27, 5803-5821 1

125 Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea. **2021**, 123, 154866 6

124 Comparison of Associations between One-Carbon Metabolism, Lipid Metabolism, and Fatty Liver Markers in Normal-Weight and Overweight People Aged 20-40 Years. **2021**, 77, 221-230 2

123 Prospective association between adherence to the Mediterranean diet and hepatic steatosis: the Swiss CoLaus cohort study. **2020**, 10, e040959 2

122 Differing Associations between Fatty Liver and Dyslipidemia According to the Degree of Hepatic Steatosis in Korea. **2019**, 8, 258-266 3

121 Endocrine causes of nonalcoholic fatty liver disease. **2015**, 21, 11053-76 43

120 Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. **2016**, 22, 2592-600 40

119 Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population. *World Journal of Hepatology*, **2020**, 12, 149-159 3.4 9


118	NAFLD mark: an accurate model based on microRNA-34 for diagnosis of non-alcoholic fatty liver disease patients. 2021 , 19, 157	0
117	The Relationship between Hepatic Steatosis, inflammation and insulin Resistance in type 2 Diabetes with Metabolic Imbalance. 2019 , 16, 13-25	
116	Noninvasive tool for the diagnosis of NAFLD in association with atherosclerotic cardiovascular risk. 2019 , 9,	0
115	The effect of elastic resistance band training with green coffee supplementation on novel hepatic steatosis biomarkers in obese women: A randomized controlled trial. 2020 , 22, 187-194	
114	Diagnostic Algorithm for the Identification of NAFLD in Primary Care. 2020 , 225-234	
113	Non-invasive Assessment of Non-alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. 2020 , 115-139	1
112	Extracellular Vesicles in Non-alcoholic Fatty Liver Disease: Key Players in Disease Pathogenesis and Promising Biomarker Tools. 2020 , 157-180	
111	Predicting and elucidating the etiology of fatty liver disease using a machine learning-based approach: an IMI DIRECT study.	
110	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. 2021 , 22,	4
109	Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. 2021 ,	2
108	First-degree family history of diabetes is associated with nonalcoholic fatty liver disease independent of glucose metabolic status. 2021 , 108083	
107	Assessment of hepatic steatosis algorithms in non-alcoholic fatty liver disease. 2018 , 22, 10-16	2
106	The prevalence and clinical implications of pancreatic fat accumulation identified during a medical check-up. 2021 , 100, e27487	
105	The prevalence and clinical implications of pancreatic fat accumulation identified during a medical check-up. 2021 , 100, e27487	0
104	Triglyceride and glucose index: a useful tool for non-alcoholic liver disease assessed by liver biopsy in patients with metabolic syndrome?. 2021 , 62, 475-480	1
103	MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.. 2021 , 8, 774079	2
102	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. 2021 ,	1
101	The Worldwide Burden of NAFLD: A Systematic Review and Meta-Analysis of Prevalence and Incidence.	

100	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. 2021 ,			1
99	Association between KLF6 rs3750861 polymorphism and plasma ceramide concentrations in post-menopausal women with type 2 diabetes.. 2022 ,			
98	The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy.. 2022 , 58,			
97	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. 2022 , 94, 216-253			5
96	Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.. 2022 , 5, e220262			0
95	Relationship between the dynamics of non-alcoholic fatty liver disease and incident diabetes mellitus.. 2022 , 12, 2538			0
94	Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank.. 2022 , 16, 325			1
93	Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.. 2022 ,			2
92	Diagnostic accuracy of the visceral adiposity index in patients with metabolic-associated fatty liver disease: a meta-analysis.. <i>Lipids in Health and Disease</i> , 2022 , 21, 28	4.4		0
91	Changes in Liver Steatosis Using Controlled Attenuation Parameter among Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals Therapy Who Achieved Sustained Virological Response.. 2022 , 12,			1
90	The triglycerides and glucose (TyG) index: a new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients.. <i>Diabetes and Metabolism</i> , 2022 , 101345	5.4		0
89	Validation of five hepatic steatosis algorithms in metabolic- associated fatty liver disease: a population based study.. 2022 ,			1
88	Long-term exposure to air pollution, habitual physical activity and risk of non-alcoholic fatty liver disease: A prospective cohort study.. 2022 , 235, 113440			0
87	Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China.. 2021 , 21, 482			0
86	Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis.. <i>Biomedicines</i> , 2021 , 10,	4.8		3
85	The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students.. 2021 , 11,			1
84	The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis.. <i>Biomedicines</i> , 2021 , 9,	4.8		1
83	Alcohol Consumption and Cardiovascular Outcomes in Patients With Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.. 2021 ,			0

82	Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approachThe institutional adaptation to existing Clinical Practice Guidelines. 2022 , 2, 12-22		1
81	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO).. 2021 , 1		1
80	Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease : A Systematic Review.. 2022 , 9, 844374		0
79	Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes.. <i>BMC Endocrine Disorders</i> , 2022 , 22, 101	3.3	0
78	Prognosis of Chronic Kidney Disease in Patients with Non-Alcoholic Fatty Liver Disease: a Northeastern Taiwan Community Medicine Research Cohort.. <i>Biomedical Journal</i> , 2022 ,	7.1	0
77	Simultaneous Imaging of Ultrasonic Backscatter and Attenuation Coefficients for Liver Steatosis Detection in a Murine Animal Model. 2022 ,		0
76	Total cholesterol to high-density lipoprotein ratio and nonalcoholic fatty liver disease in a population with chronic hepatitis B. <i>World Journal of Hepatology</i> , 2022 , 14, 791-801	3.4	
75	CROATIAN GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE.. <i>Acta Clinica Croatica</i> , 2021 , 60, 36-52	0.8	
74	Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations. 2022 ,		1
73	AEEH Consensus about detection and referral of hidden prevalent liver diseases.. <i>Gastroenterologia Y Hepatologia</i> , 2022 ,	0.9	
72	Breakthroughs in therapies for NASH and remaining challenges.. <i>Journal of Hepatology</i> , 2022 , 76, 1263-1278	3.4	1
71	Non-invasive biochemical markers and surrogate scores in evaluating non-alcoholic steatohepatitis. A narrative review.. <i>Minerva Medica</i> , 2022 ,	2.2	0
70	Combined Effects of Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease on the Risk of Cardiovascular Disease in Patients with Diabetes. <i>Biomedicines</i> , 2022 , 10, 1245	4.8	
69	Exercise Reduces the Risk of Chronic Kidney Disease in Individuals with Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study. <i>Diabetes and Metabolism</i> , 2022 , 101362	5.4	0
68	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. <i>Hormones</i> ,	3.1	0
67	Associations of serum n-3 and n-6 polyunsaturated fatty acids with prevalence and incidence of non-alcoholic fatty liver disease. <i>American Journal of Clinical Nutrition</i> ,	7	2
66	Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. <i>Cardiovascular Diabetology</i> , 2022 , 21,	8.7	0
65	Validity of fatty liver disease indices in the presence of alcohol consumption. <i>Scandinavian Journal of Gastroenterology</i> , 1-12	2.4	

64	Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in HIV-monoinfected Patients on Stable Antiretroviral Regimens. <i>Open Forum Infectious Diseases</i> ,	1	1
63	Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. <i>Obesity Reviews</i> ,	10.6	0
62	Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2022 , 21,	4.4	1
61	Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?. <i>Current Oncology</i> , 2022 , 29, 4478-4510	2.8	0
60	Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study. <i>Lipids in Health and Disease</i> , 2022 , 21,	4.4	3
59	Triglyceride and glucose index is a simple and easy-to-calculate marker associated with nonalcoholic fatty liver disease. <i>Obesity</i> , 2022 , 30, 1279-1288	8	0
58	Greater Muscular Strength Is Associated with a Lower Risk of Pulmonary Dysfunction in Individuals with Non-Alcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2022 , 11, 4151	5.1	
57	The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2022 ,	18.8	26
56	Identification of novel targets in adipose tissue involved in non-alcoholic fatty liver disease progression. <i>FASEB Journal</i> , 2022 , 36,	0.9	0
55	Advances in ultrasound elastography for nonalcoholic fatty liver disease. 2022 ,		
54	A Cross-Sectional Study of the Correlation Between the Atherogenic Index of Plasma and Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes. Volume 15, 2227-2234		
53	Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome. 2022 , 11, 4294		0
52	Liver biomarkers, genetic and lifestyle risk factors in relation to risk of cardiovascular disease in Chinese. 9,		
51	European guideline on obesity care in patients with gastrointestinal and liver diseases □Joint ESPEN/UEG guideline. 2022 ,		4
50	Controlled Attenuation Parameter Accurately Detects Liver Steatosis in People Living with HIV. Publish Ahead of Print,		
49	LCHP Diet Enriched with Cholesterol Promotes Non-Alcoholic Fatty Liver Disease in Wistar Rats. 2022 , 12, 8266		
48	Risk factors and prediction model for nonalcoholic fatty liver disease in northwest China. 2022 , 12,		0
47	European guideline on obesity care in patients with gastrointestinal and liver diseases □Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.		1

46	Etat des lieux sur la physiopathologie, le diagnostic et les traitements de la stéato-hépatite non alcoolique (NASH). 2022 ,	0
45	The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population. 2022 , 20,	0
44	Association of NAFLD with cardiovascular disease and all-cause mortality: a large-scale prospective cohort study based on UK Biobank. 2022 , 13, 204062232211224	1
43	Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) [April 2022] AWMF Registration No.: 021025. 2022 , 60, e733-e801	0
42	Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [April 2022] AWMF-Registernummer: 021025. 2022 , 60, 1346-1421	0
41	Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus Non-alcoholic fatty liver disease: a longitudinal cohort analysis. 2022 , 100762	2
40	Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal. 2022 , 12, 2287	0
39	Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk. 13,	0
38	Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality. 9,	0
37	Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn's disease but not Ulcerative Colitis: a prospective cohort study.	1
36	Correlation between Liver Fat Indices and Ultrasonography to Determine Non-alcoholic Fatty Liver Disease among Diabetic Patients in Sri Lanka. 17, 15	0
35	The Spectrum and Impact of Metabolic Dysfunction in MAFLD. A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals. 2022 ,	3
34	Association of non-alcoholic fatty liver disease with left ventricular changes in treatment-naive patients with uncomplicated hypertension. 9,	1
33	Differences in Insulin Sensitivity, Secretion, and the Metabolic Clearance Rate of Glucose in Newly Diagnosed Type 2 Diabetes Mellitus Patients: The Influences of Body Mass Index and Fatty Liver. 2022 , 20, 451-458	0
32	Association of severity of coronary and carotid atherosclerosis and functional condition of a liver at patients with stable stenocardia and obesity. 2022 , 54-60	0
31	Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients. 2022 ,	0
30	Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. 2022 ,	1
29	Non-invasive assessment of metabolic dysfunction-associated fatty liver disease. 2022 , 13, 204201882211396	0

- 28 Metabolic effects of empagliflozine. **2022**, 38-56 ○
- 27 Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. **2022**, 32, 104-140 1
- 26 Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients. ○
- 25 Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for nonalcoholic fatty liver disease. 13, ○
- 24 Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. **2022**, 1
- 23 Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery. ○
- 22 The surveillance of progression and assessment of treatment endpoint for nonalcoholic steatohepatitis. ○
- 21 Development and validation of a new nomogram to screen for MAFLD. **2022**, 21, ○
- 20 Leveraging the future of diagnosis and management of diabetes: From old indexes to new technologies. ○
- 19 Eating, diet, and nutrition for the treatment of NAFLD. ○
- 18 Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease. **2023**, 21, ○
- 17 Prevalence of non-alcoholic fatty liver disease and its association with lifestyle habits in adults in Chile: a cross-sectional study from the National Health Survey 2016-2017. 1-30 ○
- 16 Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes. **2023**, 37, 108405 ○
- 15 Utility of 99mTc-Sestamibi Heart/Liver Uptake Ratio in Screening Nonalcoholic Fatty Liver Disease During Myocardial Perfusion Imaging. ○
- 14  **2023**, 18, 362-380 ○
- 13 Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. **2023**, 24, 2844 ○
- 12 The Link between NAFLD and Metabolic Syndrome. **2023**, 13, 614 ○
- 11 AEEH "Consensus about detection and referral of hidden prevalent liver diseases". **2023**, ○

- 10 Effects of Monacolin K in Nondiabetic Patients with NAFLD: A Pilot Study. **2023**, 15, 1887
- 9 Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study. **2023**, 108475
- 8 The Past, Present, and Future of Noninvasive Test in Chronic Liver Diseases. **2023**, 107, 397-421
- 7 Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients. **2023**,
- 6 Fasting serum fructose is associated with metabolic dysfunction-associated fatty liver disease: A prospective study.
- 5 Significant Dose-Response Association of Physical Activity and Diet Quality With Mortality in Adults With Suspected NAFLD in a Population Study. **2023**, Publish Ahead of Print,
- 4 Clinical-radiomic analysis for non-invasive prediction of liver steatosis on non-contrast CT: A pilot study. 14,
- 3 Sugar-sweetened beverages, low/no-calorie beverages, fruit juice and non-alcoholic fatty liver disease defined by fatty liver index: the SWEET project. **2023**, 13,
- 2 MLX plays a key role in lipid and glucose metabolism in humans: Evidence from in vitro and in vivo studies. **2023**, 155563
- 1 Population-Attributable Fractions of Nonalcoholic Fatty Liver Disease on All-Cause and Cause-Specific Mortality Risk: How Large is the Impact?. **2023**,